NASDAQ:SPNE

SeaSpine (SPNE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$8.43
$9.67
50-Day Range
$7.03
$9.54
52-Week Range
$5.48
$14.23
Volume
1.16 million shs
Average Volume
822,700 shs
Market Capitalization
$354.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SeaSpine MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
-0.11mentions of SeaSpine in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.62) to ($1.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.25 out of 5 stars

Medical Sector

901st out of 921 stocks

Surgical & Medical Instruments Industry

96th out of 98 stocks

SPNE stock logo

About SeaSpine Stock (NASDAQ:SPNE)

As of January 4, 2023, SeaSpine Holdings Corporation was acquired by Orthofix Medical Inc. SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.

SPNE Stock News Headlines

Q1 2024 Orthofix Medical Inc Earnings Call
READ THIS – If You Missed Out On The AI Boom
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Prosecutors investigate spinal implant
READ THIS – If You Missed Out On The AI Boom
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Orthofix Reports Third Quarter 2023 Results
Vaping and Its Effects on Spine Health
Orthofix Announces Changes to Board of Directors
SeaSpine (NASDAQ: SPNE)
Spinal Devices Market Size by 2031
See More Headlines
Receive SPNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SeaSpine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/28/2021
Today
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:SPNE
Fax
N/A
Employees
523
Year Founded
N/A

Profitability

Net Income
$-54,350,000.00
Pretax Margin
-28.83%

Debt

Sales & Book Value

Annual Sales
$191.45 million
Book Value
$8.57 per share

Miscellaneous

Free Float
33,736,000
Market Cap
$354.92 million
Optionable
Optionable
Beta
1.31
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Keith C. Valentine (Age 54)
    Pres, CEO & Director
    Comp: $977.29k
  • Mr. John J. Bostjancic (Age 51)
    Sr. VP, CFO, COO & Treasurer
    Comp: $556.62k
  • Dr. Beau Standish P.Eng. (Age 42)
    Ph.D., Pres of Enabling Technologies
    Comp: $345.15k
  • Dr. Frank Vizesi
    Chief Scientific Officer
  • Carrie Mendivil
    Head of Investor Relations
  • Mr. Patrick L. Keran J.D. (Age 50)
    Sr. VP, Gen. Counsel & Sec.
  • Mr. John J. Winge (Age 55)
    VP of Sales
  • Ms. Hollis Winkler (Age 47)
    Sr. VP of HR
  • Mr. Tyler P. Lipschultz (Age 55)
    Sr. VP of Orthobiologics & Bus. Devel.
  • Mr. Dennis L. Cirino (Age 52)
    Sr. VP of Global Spinal Systems

SPNE Stock Analysis - Frequently Asked Questions

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Co. (NASDAQ:SPNE) released its quarterly earnings results on Thursday, October, 28th. The medical equipment provider reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.17. The medical equipment provider had revenue of $46.45 million for the quarter, compared to the consensus estimate of $45.66 million. SeaSpine had a negative net margin of 28.22% and a negative trailing twelve-month return on equity of 22.16%. SeaSpine's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the company earned ($0.24) earnings per share.

What is Keith Valentine's approval rating as SeaSpine's CEO?

23 employees have rated SeaSpine Chief Executive Officer Keith Valentine on Glassdoor.com. Keith Valentine has an approval rating of 79% among the company's employees.

What other stocks do shareholders of SeaSpine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SeaSpine investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Kura Oncology (KURA), Recro Pharma (REPH), Rigel Pharmaceuticals (RIGL), Spectrum Pharmaceuticals (SPPI), ViewRay (VRAY), Verastem (VSTM) and Akorn (AKRX).

This page (NASDAQ:SPNE) was last updated on 5/10/2024 by MarketBeat.com Staff

From Our Partners